🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interested in how our NASH model is improved over other models? See the publication by Melior’s director of metabolic disorders where it was established. ow.ly/ZM9O30kjEJ5

Evaluate your inflammation/arthritis therapies with one of our models. Visit our models page: bit.ly/2fcSikK #arthritis #pharma

We are partnering with SFA Therapeutics on grant directed to COVID-19 Ira C. Spector businesswire.com/news/home/2020…

Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic | Business Wire businesswire.com/news/home/2021…

We are thrilled to be working with the Adhera team and are pleased that they share our vision for the product potential of armesocarb and the streamlined clinical development path, based upon the product’s history, that we have developed businesswire.com/news/home/2021…

twoXAR Announces Preclinical Proof-of-Concept Data on Type 2 Diabetes Candidate | Business Wire businesswire.com/news/home/2017…

Lots of great connections and discussions at the 6th annual drug repositioning conference this week in Chicago!

A great article discussing what is needed for a drug repurposing pipeline ncbi.nlm.nih.gov/pubmed/28369768

August 21-23 Melior will be at the IPF Summit in Boston. Learn how we are helping to advance these therapies. ipf-summit.com

See our recent feature article in Science Exchange discussing the theraTRACE and opioidTRACE platforms. bit.ly/2y0NPZ9

Melior’s OpiodTRACE platform helps evaluate therapies for pain management. Learn more today: bit.ly/2xeBQdl #pharma

Melior Pharma Initiates Phase 2B Study with MLR-1023 for Type 2 Diabetes ~ First Patient of 400 Dosed, 61 sites businesswire.com/news/home/2017…

See our publication in “Drug Discovery Today: Technologies” reviewing our drug repositioning approach and MLR-1023. bit.ly/2r50FFx

Let Melior evaluate your inflammation/arthritis therapies with one of our models. Visit our models page: bit.ly/2fcSikK #arthritis

Need evaluation for lung or liver fibrosis? Melior’s models can help. Liver bit.ly/2eYlIG4 Lung bit.ly/2xpvFUz

We will be at SFN this week. Please consider stopping by our poster on Tuesday (1pm – 5pm; Poster ID: 573.08 / T9). Here we describe the story of our Parkinson’s disease candidate MLR-1019.

We offer a wide array of animal in various therapeutic areas. Interested in learning more? Our models page is a great place to start. bit.ly/2fcSikK

Learn about Melior’s partnership approach and collaborative discoveries Partnership: bit.ly/2DJgkhd Collaborative discoveries: bit.ly/2FsQiQ0

Melior Discovery has been recognized as a top life science company of 2018 by the Philadelphia Business Journal. Learn more at meliordiscovery.com

Melior is excited to announce the launch of our NASH (Non-Alcoholic Steatohepatitis)/NAFLD mouse model. See the link below to learn more. bit.ly/2rFGGfk